Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial

AMSTERDAM, June 15, 2012 /PRNewswire/ --

"Hodgkin lymphoma has become one of the most curable malignancies in adults," was stated by Dr Andreas Engert, Professor of Hematology at the University Hospital of Cologne in Germany.   Results of the German Hodgkin Study Group (GHSG) HD 15 trial are presented at the 17^th Congress of the European Hematology Association in Amsterdam.

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear. We thus conducted a prospectively randomized clinical trial comparing the standard of care (8 x BEACOPPescalated) with two reduced-intensity chemotherapy variants. Chemotherapy was followed by positron emission tomography (PET) guided radiotherapy. In total, 2182 patients with newly diagnosed advanced stage Hodgkin lymphoma were randomized. Treatment with 6 cycles of BEACOPPescalated was not only better tolerated than 8 cycles but resulted in improved tumor control (89.3% versus 84.4%) and overall survival (94.5% versus 91.9%).  This was in part due to a lower mortality with 6 cycles as compared to 8 in terms of treatment related events (0.8% versus 2.1%) and secondary malignancies (0.7% versus 1.8%). In addition, the PET-guided radiotherapy resulted in a substantially reduced number of patients radiated in the present HD15 trial (11%). The outcome in HD15 was comparable to the prior HD9 study in which 70% had received additional radiotherapy. Thus, we suggested that 6 cycles of BEACOPPescalated is the treatment of choice for advanced stage Hodgkin lymphoma; PET performed after chemotherapy can guide the need of additional radiotherapy in this setting.  

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17^th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.

SOURCE European Hematology Association